Regular ArticleInhibitory Effects of Angiotensin Receptor Blockers on CYP2C9 Activity in Human Liver Microsomes
References (23)
- et al.
The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution
J. Biol. Chem.
(2004) - et al.
Compound lipophilicity for substrate binding to human P450s in drug metabolism
Drug Discovery Today
(2004) - et al.
Current status of antihypertensive prescription and associated blood pres sure control in Japan
Hypertens. Res.
(2006) Cardium Study #58 Hypertension October 2004
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
J. hum. Hypertens.
(2000)- et al.
Drug interactions with angiotensin receptor blockers: A comparison with other antihypertensives
Drug Safety
(2003) - et al.
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
J. Med. Chem.
(2003) - et al.
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Br. J. Clin. Pharmacol.
(1998) - et al.
Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
Drug Metab. Dispos.
(1995) - et al.
Role of CYP2C9 polymorphism in losartan oxidation
Drug Metab. Dispos.
(2001)
Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
Drug Metab. Disps.
(1999)
Cited by (28)
Pharmacogenomics Informs Cardiovascular Pharmacotherapy
2022, Methods in Molecular BiologyEffects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center
2021, European Journal of Clinical Pharmacology
Copyright © 2007 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.